Fed. Circ. Limits Safe Harbor For Post-Approval Conduct
The Federal Circuit's Nov. 10 decision in Momenta Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc. ("Momenta II"),[1] which reversed its earlier decision in Momenta Pharmaceuticals Inc. v. Amphastar Pharmaceuticals Inc. ("Momenta I"),...To view the full article, register now.
Already a subscriber? Click here to view full article